Viral hepatitis, new viruses and therapies

Current Opinion in Infectious Diseases

Volumn 9, Issue 5, 1996, Pages 359-364

  McCarron, Brendan ^a   Main, Janice ^a   Thomas, Howard C ^a  

^a ST MARY S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; FAMCICLOVIR; FIALURIDINE; GANCICLOVIR; LAMIVUDINE; NUCLEOSIDE ANALOG; RECOMBINANT ALPHA INTERFERON; RIBAVIRIN; THYMOSIN; VIDARABINE PHOSPHATE;

HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HEPATITIS C VIRUS; HEPATITIS VIRUS; HUMAN; INTRAMUSCULAR DRUG ADMINISTRATION; REVIEW; SIDE EFFECT; VIRUS HEPATITIS;

EID: 0029800168     PISSN: 09517375     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001432-199610000-00013     Document Type: Review

References (62)

1. Moradpour D, Wands JR: Understanding Hepatitis B infection. N Engl J Med 1995, 332:1092-1093.
2. Carman WF, Zanetti AR, Karayiannis P, Waters J, Manzillo G, Tanzi E, Zuckerman AJ, Thomas HC: Vaccine-induced escape mutants of hepatitis B virus. Lancet 1990, 336:325-329.
3. Carman WF, Korula J, Wallace L, MacPhee R, Mimms L, Decker R: Fulminant reactivation of hepatitis B due to envelope protein mutant that escaped detection by monoclonal HBsAg ELISA. Lancet 1995, 345:1406-1407.
4. Hou J, Karayiannis P, Waters J, Luo K, Liang C, Thomas HC: A unique insertion in the S gene of surface antigen-negative hepatitis B virus Chinese carriers. Hepatology 1995, 21:273-278.
5. Carman WF, Jacyna MR, Hadziyannis S, Karayiannis P, McGarvey MJ, Makris A, Thomas HC: Mutation preventing formation of hepatitis HB e antigen in chronic hepatitis B virus infection. Lancet 1989, ii:588-591.
6. Lok ASF, Akarca V, Greene S: Mutations in the pre-core region of hepatitis B virus serve to enhance the stability of the secondary structure of the pre-genome encapsidation signal. Proc Natl Acad Sci USA 1994, 91:4077-4081.
7. Lindh M, Furuta Y, Vahlne A, Norkrans G, Horal P: Emergence of precore TAG mutation during hepatitis B e seroconversion and its dependence on pregenomic base pairing between nucleotide 1858 and 1896. J Infect Dis 1995, 172:1343-1347.
8. Hadziyannis SJ: Hepatitis B e antigen negative chronic hepatitis B: from clinical recognition to pathogenesis and treatment. Viral Hep Rev 1995, 1:7-36.
9. Carman WF, Fagan EA, Hadzyiannis S, Karayiannis P, Tassopoulos NC, Williams R, Thomas HC: Association of a pre-core genome variant of hepatitis B virus with fulminant hepatitis. Hepatology 1991, 14:219-222.
10. Fukuda R, Xuanthanh N, Ishimura N, Ishihara S, Chowdhury A, Kohge N, Akagi S, Watanabe M, Fukumoto S: X gene and precore region mutations in the hepatitis B virus genome in persons positive for antibody to hepatitis B e antigen: comparison between asymptomatic 'healthy' carriers and patients with severe chronic active hepatitis. J Infect Dis 1995, 172:1191-1197. Of 28 patients, with a pre-core stop codon mutation, 17 out of 19 who were asymptomatic and had low replication levels of HBV had an X gene mutation, but none out of nine symptomatic patients with high HBV replication levels had an X gene mutation. An interesting study although dual mutations may be an exception rather than the rule?
11. Sato S, Suzuki K, Akahane Y, Akamatsu K, Yunomura K, Tsuda F, Tanaka T, Okamoto H, Miyakawa Y, Mayumi M: Hepatitis B virus strains with mutations in the core promoter in patients with fulminant hepatitis. Ann Intern Med 1995, 122:241-248.
12. Lindh M, Furuta Y, Ljunggren KK, Norkans G, Horal P: Detection of hepatitis B virus precore TAG mutant by an amplification-created restriction type method. J Infect Dis 1995, 171:194-197.
13. Hadziyannis S, Bramou T, Makris A, Moussoulis G, Zignego L, Papaioannou C: Interferon-alpha 2b treatment of HBeAg negative/serum HBV DNA positive chronic hepatitis type B. J Hepatol 1990, 11(suppl 1):S133-S136.
14. Thursz MR, Kwiatkowski D, Allsopp CEM, Greenwood BM, Thomas HC, Hill AVS: Association between an MHC class II allele and clearance of hepatitis B virus in the Gambia. N Engl J Med 1995, 332:1065-1069. HLA-DRB1* 1302 was found in 26.6% of 218 children (under 10 years of age) with transient HBV compared with 16.2% of 185 children with persistent HBV, and in 25.6% of 195 adults with transient HBV compared with 7.5% of 40 adults with persistent HBV.
15. Wong JB, Koff RS, Tine F, Pauker SG: Cost-effectiveness of interferon-alpha 2b treatment for hepatitis B e antigen-positive chronic hepatitis B. Ann Intern Med 1995, 122:664-675. With therapy 45.6% cleared HBeAg and 7.7% cleared HBsAg compared with 9.1% and 1.7% clearing HBeAg and HBsAg, respectively, without therapy. Life expectancy increased by 3.1 years with quality adjusted life years increasing by 3.4 years.
16. Severini A, Liu XY, Wilson JS, Tyrrell DLJ: Mechanism of inhibition of duck hepatitis B virus polymerase by (-)-beta-L-2′,3′-dideoxy-3′-thiacytidine. Antimicrob Agents Chemother 1995, 39:1430-1435.
17. Dienstag JL, Perrillo RP, Schiff ER, Bartholomew M, Vicary C, Rubin M: A preliminary trial of lamivudine for chronic hepatitis B infection. N Engl J Med 1995, 333:1657-1661. In 32 chronic HBV patients lamivudine reduced HBV DNA after 12 weeks of treatment. In most cases HBV DNA levels increased again, although 19% had prolonged HBV DNA suppression and normalization of ALT and 12% cleared HBeAg. After 36 weeks of 300 mg of lamivudine, 18% cleared HBeAg.
18. Nowak MA, Bonhoeffer S, Hill AM, Boehme R, Thomas HC, McDade H: Viral dynamics in hepatitis B infection. Proc Natl Acad Sci USA 1996, 93:4398-4402.
19. Marcellin P, Pouteau M, Loriot MA, Boyer N, Desgos F, Cales P, Bettan L, Bacq Y, Coppere H, Grange JD et al.: Adenine arabinoside 5′ monophosphate in patients with chronic hepatitis B: comparison of the efficacy in patients with high and low viral replication. Gut 1995, 36:422-426.
20. McKenzie R, Fried MW, Sallie R, Conjeevaram H, Di Biscegli AM, Park Y, Savarese B, Kleiner B, Tsokos M, Luciano C et al.: Hepatic failure and lactic acidosis due to fialuridine (FIAU), an investigational nucleoside analogue for chronic hepatitis B. N Engl J Med 1995, 333:1099-1105.
21. Cui L, Yoon S, Schinazi R, Sommadossi JP: Cellular and molecular events leading to mitochondrial toxicity of 1-(2-deoxy-2-fluro-1-b-d-arabinofuranosyl)-5-idouracil in human liver cells. J Clin Invest 1995, 95:555-563.
22. Main J, Brown JL, Howels C, Galassini R, Crossley M, Karayiannis P, Georgiou P, Atkinson G, Thomas HC: A double blind placebo controlled study to assess the effect of famciclovir on viral replication in patients with chronic hepatitis B virus infection. J Viral Hepatitis 1996, 3:211-215.
23. Wang YL, Luscombe C, Bowden S, Shaw T, Locarnini S: Inhibition of duck hepatitis B virus DNA replication by anti-viral chemotherapy with ganciclovir-nalidixic acid. Antimicrob Agents Chemother 1995, 39:556-558.
24. Gish RG, Lau JY, Brooks L, Fang JW, Steady SL, Imperial JC, Kennedy RG, Esquivel CO, Keeffe GB: Ganciclovir treatment of hepatitis B infection in liver transplant recipients. Hepatology 1996, 23:1-7.
25. Zhang ZX, Chen M, Sonnerborg A, Weiland O, Sallberg M: Distinguishing acute from symptomatic chronic hepatitis C virus (HCV) infection by site-directed serology of the HCV structural proteins. J Infect Dis 1995, 171:1356-1359.
26. Chemello L, Bonetti P, Cavalletto L, Talato F, Donadon V, Casarin P, Belussi F, Frezza M, Noventa F, Pontisso P et al.: Randomised trial; comparing 3 different regimens of alpha-2b-interferon in chronic hepatitis C. Hepatology 1995, 22:700-706.
27. Poynard T, Bedossa P, Chevallier M, Mathurin P, Lemonnier C, Trepo C, Couzigou P, Payen JL, Sajus M, Costa JM et al.: A comparison of three interferon-alpha 2b regimens for the long term treatment of chronic non-A, non-B hepatitis. N Engl J Med 1995, 332:1457-1462.
28. Hino K, Okuda M, Konishi T, Ishiko H, Okita K: Serial assays of hepatitis C virus RNA in serum for predicting response of interferon alpha therapy. Dig Dis Sci 1995, 40:14-20.
29. Booth JCL, Foster GR, Kumar U, Gallassini R, Goldin RD, Brown JL, Thomas HC: Chronic hepatitis C virus infections: predictive value of genotype and level of viraemia on disease progression and response to interferon-alpha. Gut 1995, 36:427-432
30. Chayama K, Tsubuta A, Kobayashi M, Hashimoto M, Miyano Y, Koike H, Kobayashi M, Koida I, Arase Y, Saitoh S et al.: A pilot study of corticosteroids priming for lymphoblastoid interferon alfa in patients with chronic hepatitis C. Hepatology 1996, 23:953-957.
31. Shindo M, Arai K, Sokawa Y, Okuno T: Hepatitic hepatitis C virus RNA as a predictor of long term response to interferon alpha therapy. Ann Intern Med 1995, 122:586-591.
32. Nishiguchi S, Kuroki T, Nakatani S, Morimoto H, Takeda T, Nakajima S, Shiomi S, Seki S, Kobayashi K, Otani S: Randomised trial of effect of interferon alpha on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis. Lancet 1995, 346:1051-1055. In this study 45 out of 90 patients with cirrhotic chronic hepatitis C were treated with IFN for 24 weeks and followed up for 2-7 years. A total of 4% of IFN-treated patients developed HCC and 38% of non-IFN, symptomatic treated patients developed HCC.
33. Demitri MS, Poussin K, Baccarini P, Pontisso P, Derrico A, Simon N, Grigioni W, Alberti A, Beaugrand M, Pisi E et al.: HCV-associated liver cancer without cirrhosis. Lancet 1995, 345:413-415.
34. Enomoto N, Sakuma I, Asahina Y, Kurosaki M, Murakami T, Yamamoto C, Izumi N, Marumo F, Sato C: Comparison of full length sequencies of interferon sensitive and resistant hepatitic C virus 1b. J Clin Invest 1995, 96:224-230. In determining that the IFN sensitivity region is at the NS5A region, around codon 2218, the specific nature of these mutations might make it possible to predict the prognostic effects of IFN therapy.
35. Dusheiko G, Roberts JA: Treatment of chronic type B and C hepatitis with interferon alfa: an economic evaluation. Hepatology 1995, 22:1863-1873.
36. Di-Bisceglie AM, Conjeevaram HS, Fried MW, Sallie R, Park Y, Yurdaydin C, Swam M, Klein DE, Mahaney K, Hoofnagle JH, Wright D: Ribavarin as therapy for chronic hepatitis - a randomised double blind, placebo-controlled trial. Ann Intern Med 1995, 123:897-903. Ribavarin was given to 29 patients for 12 months in a double-blind randomized placebo-controlled study, transaminase levels fell to normal or nearly normal in 35% of patients, but a sustained biochemical response was seen in only 7% of them.
37. Dusheiko G, Main J, Thomas HC, Reichard O, Lee C, Dhillon A, Rassam S, Fryden A, Reesink H, Bassendine M et al.: Ribavarin treatment for patients with chronic hepatitis C: results of a placebo-controlled study. J Hepatol 1996, in press.
38. Braconier JH, Paulsen O, Engman K, Widell A: Combined alpha-interferon and ribavarin treatment in chronic hepatitis C: a pilot study. Scand J Infect Dis 1995, 27:325-329.
39. Brillianti S, Garson J, Foli M, Whitby K, Deaville R, Masci C, Miglioli M, Barbara L: A pilot study of combination therapy with ribavarin plus interferon alfa for interferon alfa resistant hepatitis C. Gastroenterology 1994, 107:812-817.
40. Chemello L, Cavaletto L, Bernardinello E, Guido M, Pontisso P, Alberti A: The effect of interferon alfa and ribavarin combination therapy in naive patients with chronic hepatitis C. J Hepatol 1994, 23(suppl 2):S8-S12.
41. Sharman KE, Sjogren MH, Creager R: Hepatitis C response to combined therapy with thymosin and alpha-1 -interferon [Abstract]. Hepatology 1994, 20:207A.
42. Arankalle VA, Tsarev SA, Chadha MS, Alling DW, Emerson SU, Banerjee K, Purcell RH: Age-specific prevalence of antibodies to hepatitis A and E viruses in Pune, India, 1982 and 1992. J Infect Dis 1995, 171:447-450.
43. Skidmore SJ: Hepatitis E. BMJ 1995, 310:414-415.
44. Clayson ET, Myint KSA, Snitbhan R, Vaughn DW, Innis BL, Chan L, Cheung P, Shrestha MP: Viremia, fecal shedding, and IgM and IgG responses in patients with hepatitis E. J Infect Dis 1995, 172:927-933.
45. Zanetti AR, Dawson GJ: Hepatitis type E in Italy: a seroepidemiological study. J Med Virol 1994, 42:318-320.
46. Pisanti FA, Coppola A, Galli C: Association between hepatitis C and hepatitis E viruses in Southern Italy. Lancet 1994, 344:746-747.
47. Montella F, Rezza G, Di-Sora F, Pezzotti P, Recchia O: Association between hepatitis E virus and HIV infection in homosexual men [Letter]. Lancet 1994, 344:1433.
48. Khuroo MS, Teli MR, Skidmore S, Sofi MA, Khuroo M: Incidence and severity of viral hepatitis in pregnancy. Am J Med 1981, 70:252-255.
49. Tsarev SA, Tsareva TS, Emerson SU, Rippy MK, Zack P, Shapiro M, Purcell RH. Experimental hepatitis E in pregnant rhesus monkeys: failure to transmit hepatitis E virus (HEV) to offspring and evidence of naturally acquired antibodies to HEV. J Infect Dis 1995, 172:31-37.
50. Khuroo MS, Kamili S, Jameel S: Vertical transmission of hepatitis E virus. Lancet 1995, 345:1025-1026.
51. Dienhardt F, Holmes AW, Capps RB, Popper H: Studies on the transmission of human viral hepatitis to marmoset monkeys. Transmission of disease, serial passage and description of liver lesions. J Exp Med 1967, 125:673-687.
52. Simons JN, Pilot-Matias TJ, Leary TP, Dawson GJ, Desai SM, Schlauder GG, Muerhoff AS, Erker JC, Buijk SL, Chalmers ML et al.: Identification of two flavi-like genomes in the GB hepatitis agent. Proc Natl Acad Sci USA 1995, 92:3401-3405.
53. Schlauder GG, Dawson GJ, Simons JN, Pilot-Matias TJ, Guiterrez RA, Heynen CA, Knigge MF, Kurpiewski GS, Buijk SL, Leary TP, et al.: Molecular and serologic analysis in the transmission of the GB hepatitis agent. J Med Virol 1995, 46:81-90.
54. Schlauder GG, Pilot-Matias TJ, Gabriel GS, Simons JN, Muerhoff AS, Dawson GJ, Mushahwar IK: Origin of GB hepatitis viruses. Lancet 1995, 346:447-448.
55. Simons J, Leary TP, Dawson GJ, Pilot-Matias TJ, Muerhoff AS, Schlauder GG, Desai SM, Mushahwar IK: Isolation of novel virus-like sequences associated with human hepatitis. Nature Med 1995, 1:564-569. GBV-C was isolated from human sera containing antibodies recognized by GBV-A ± GBV-B recombinant proteins. Identified sera was subjected to PCR studies to identify a genomic sequence suggesting a novel virus, designated GBV-C.
56. Linnen J, Wages J, Zhen-Yong Zhang-Keck, Fry K, Crawczynski K, Alter H, Koonin E, Gallagher M, Alter M, Hadziyannis S, et al.: Molecular cloning and disease association of hepatitis G virus: a transfusion-transmissable agent. Science 1996, 271:505-508. A multi-centre report describing the molecular cloning of HGV identified from the plasma of a patient with chronic hepatitis. HGV was associated with acute and chronic hepatitis (persistent) viraemia being detected for up to 9 years) and was transmissible by transfusion.
57. Neilson J, Harrison P, Milligan DW, Skidmore SJ, Collingham KE: Hepatitis G virus in long-term survivors of haematological malignancy. Lancet 1996, 347:1632-1633.
58. Aikawa T, Sugai Y, Okanoto H: Hepatitis G infection in drug abusers with hepatitis C. N Engl J Med 1996, 334:195-196.
59. Masuko K, Mitsui T, Iwano K, Yamazaki C, Okuda K, Meguro T, Murayama N, Inoue T, Tsuda F, Okamoto H et al.: Infection with hepatitis GB virus C in patients on maintenance hemodialysis. N Engl J Med 1996, 334:1485-1490.
60. Karayiannis P, McGarvey MJ: The GB hepatitis viruses. J Viral Hep 1995, 2:221-226.
61. Yoshiba M, Okamoto H, Mishiro S: Detection of the GBV-C hepatitis virus genome in serum from patients with fulminant hepatitis of unknown origin. Lancet 1995, 346:1131-1132.
62. Sallie R, Shaw J, Murtimer D: GBV-C virus and fulminant hepatic failure [Letter]. Lancet 1996, 347:1552.